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Referral criteria for outpatient specialty palliative cancer care: 
an international consensus
David Hui, Masanori Mori, Sharon M Watanabe, Augusto Caraceni, Florian Strasser, Tiina Saarto, Nathan Cherny, Paul Glare, Stein Kaasa, 
Eduardo Bruera
Although outpatient specialty palliative-care clinics improve outcomes, there is no consensus on who should be 
referred or the optimal timing for referral. In response to this issue, we did a Delphi study to develop consensus on a 
list of criteria for referral of patients with advanced cancer at secondary or tertiary care hospitals to outpatient palliative 
care. 60 international experts (26 from North America, 19 from Asia and Australia, and 11 from Europe) on palliative 
cancer care rated 39 needs-based criteria and 22 time-based criteria in three iterative rounds. Nearly all experts 
responded in each round. Consensus was deﬁ ned by an a-priori agreement of 70% or more. Panellists reached 
consensus on 11 major criteria for referral: severe physical symptoms, severe emotional symptoms, request for 
hastened death, spiritual or existential crisis, assistance with decision making or care planning, patient request for 
referral, delirium, spinal cord compression, brain or leptomeningeal metastases, within 3 months of advanced cancer 
diagnosis for patients with median survival of 1 year or less, and progressive disease despite second-line therapy. 
Consensus was also reached on 36 minor criteria for specialist palliative-care referral. These criteria, if validated, 
could provide guidance for identiﬁ cation of patients suitable for outpatient specialty palliative care.
Introduction
A growing body of evidence1–5 from the past decade 
suggests that early involvement of specialty palliative 
care, concurrent with routine oncological care, is 
associated with improved quality of life, symptom 
burden, patient and caregiver satisfaction, and possibly 
survival. Oncologists deliver high-quality primary 
palliative care on the front lines.6,7 However, some 
patients have more complex supportive care needs and 
would beneﬁ t from referral to a palliative-care specialist. 
Outpatient clinics are crucial for early palliative access 
for patients with cancer in the ambulatory setting while 
they are still undergoing treatment,8–11 and are a major 
indicator of integration.12 A 2014 study5 showed that, 
compared with inpatient palliative-care consultation, 
referral to outpatient palliative care is associated with 
signiﬁ cant improvement in end-of-life outcomes.
Several organisations, such as the European Society 
for Medical Oncology (ESMO), the American Society 
of Clinical Oncology, WHO, and the National 
Comprehensive Cancer Network (NCCN), along with 
many opinion leaders, have called for timely specialty 
palliative-care referral and for more resources to 
support palliative-care programmes.13–15 However, a 
2016 systematic review16 showed heterogeneity in terms 
of who should be referred and when referral should 
occur. This lack of consensus partly contributes to 
inconsistent and delayed referrals. To optimise the use 
of scarce palliative-care resources, patients need to be 
referred at the right time for the right reasons. 
Therefore, consensus on simple, robust, and valid 
referral criteria is urgently needed.
A consensus set of referral criteria would allow 
referring clinicians to identify appropriate patients 
for palliative-care interventions, administrators to 
benchmark their programmes, researchers to standardise 
trial inclusion criteria, and policy makers to develop 
clinical care pathways and allocate appropriate resources. 
As part of the Delphi study, we aimed to reach an 
international consensus among experts on referral 
criteria to outpatient palliative care for patients with 
advanced cancer who are being treated at secondary or 
tertiary care hospitals with an interdisciplinary palliative-
care team in place (assuming that service delivery is not 
an issue).
Methods
Participant selection
This study was approved by the institutional review board 
at MD Anderson Cancer Center (Houston, TX, USA), 
which waived the need for informed consent. Our Delphi 
panel consisted of international experts who have an 
in-depth understanding of outpatient palliative cancer 
care through their training, clinical practice, or research. 
We included only individuals who met all four of the 
following eligibility criteria: a physician with an active 
(at least 20% clinical) specialty clinical practice in either 
palliative care or oncology, or both, with at least 5 years of 
post-qualiﬁ cation clinical experience; working at a center 
with outpatient palliative-care access; at least one of 
board certiﬁ cation or equivalent in both oncology and 
palliative care, have published in the area of integration 
of palliative care and oncology in the past 10 years, or 
have been involved in national or international 
palliative-care guideline development on the topic of 
integration; and able to communicate in written English.
We searched for potentially eligible candidates on the 
basis of a literature review of outpatient palliative 
care; membership of the Multinational Association of 
Supportive Care in Cancer (MASCC) Palliative Care 
Study Group, the NCCN Palliative Care Guideline 
Committee, or the ESMO Palliative Care Working Group; 
and nominations by the steering committee. We emailed 
potentially eligible candidates an invitation outlining the 
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eligibility criteria and the study process. To maximise 
inclusion, we also asked potential individuals to send us 
the names of other potential candidates, whom we 
subsequently contacted (the criteria outlined previously 
were applied to these recommendations). All individuals 
who responded, conﬁ rmed that they met the eligibility 
criteria, and expressed a willingness to participate were 
included in the study.
Eligibility criteria
Because referral criteria vary substantially by cancer 
stage, clinical setting, and local resource availability, we 
speciﬁ cally focused on referral criteria for patients with 
advanced cancer being treated at secondary or tertiary 
care hospitals with an interdisciplinary palliative-care 
team in place, assuming that service delivery is not an 
issue. The list of potential criteria was generated on the 
basis of a systematic review16 by our group, in which we 
identiﬁ ed 20 unique categories of criteria. Six of these 
categories were commonly cited for referral—
two time-based criteria (ie, cancer trajectory and 
prognosis) and four needs-based criteria (ie, physical 
symptoms, performance status, end-of-life care planning, 
and psychosocial distress). Before each Delphi round, 
steering committee members reviewed and revised the 
list of referral criteria and speciﬁ c wording used.
Process
Between Sept 28, 2015, and Feb 16, 2016, we used the 
Qualtrics Survey Software (Qualtrics, Provo, UT, USA) to 
administer web-based surveys to our participants. Our 
Delphi study consisted of three rounds, each lasting 
4 weeks and spaced 2–6 weeks apart (ﬁ gure 1). 
Non-respondents were sent weekly email reminders. We 
did not provide any ﬁ nancial incentives.
The ﬁ rst Delphi round included 20 time-based criteria 
and 36 needs-based criteria. For each time-based 
criterion, we asked panellists to independently state the 
appropriateness of timing on a ﬁ ve-point Likert scale 
(“much too early”, “too early”, “appropriate”, “too late”, 
and “much too late”). Answers that were marked 
as “appropriate” were considered for consensus 
determination. For each needs-based criterion, we also 
used a ﬁ ve-point Likert scale (“strongly agree”, “agree”, 
“neither agree nor disagree”, “disagree”, and “strongly 
disagree”). “Strongly agree” and “agree” were combined 
and coded as an overall agreement in our analysis. A 
consensus was deﬁ ned a priori as a minimum of 70%. 
We also collected basic demographic information from 
the experts, such as age group, type of clinical practice, 
and years of experience (appendix).
The second Delphi round included 20 putative 
time-based criteria and 39 putative needs-based criteria, 
with three new needs-based indicators added (unrealistic 
hope or denial, participation in phase 2 or 3 clinical trials, 
patient expected to have aggressive disease course at the 
time of diagnosis [eg, survival <6 months]) on the basis 
of participants’ comments after the ﬁ rst round. During 
the ﬁ rst round, some panellists commented on the need 
to identify not only which criteria were appropriate but 
also their relative importance. For each indicator in the 
second round, participants were provided with the mean 
percentage of agreement from the previous round 
(among those who participated), and asked if each item 
was appropriate as a referral criterion. If experts 
answered “yes”, they were then asked whether the item 
should be a major (ie, its presence in isolation is suﬃ  cient 
to trigger referral) or minor (ie, other similar-level criteria 
would be needed to trigger referral) criterion. 
Furthermore, they were asked to rate the relative 
importance of each criterion from 0 (least important) to 
10 (most important).
The third Delphi round focused on a shortlist of criteria 
with 70% or higher agreement for being a major criterion 
in the second round. Experts were asked to express their 
level of agreement (from “strongly agree” to “strongly 
disagree”). Any criterion that was marked as “appropriate” 
and reached consensus in the second round and was not 
included as a major criterion was classiﬁ ed as a minor 
criterion. The experts were then asked to rate the major 
criteria on a numeric scale from 0 (“not at all”) to 10 
(“very much”) in regard to whether they were clearly 
stated, objective, amenable to accurate assessment, 
amenable to being used for routine screening in the 
oncology practice, useful to facilitate outpatient 
palliative-care referral in their own countries, and useful 
to facilitate outpatient palliative-care referral at their own 
institutions.
We used the McNemar exact test to determine the 
stability of responses between the second and third 
Delphi rounds. We did our statistical analyses with Stata 
(version 12.1).
See Online for appendix
Figure 1: Delphi process to reach consensus for outpatient palliative-care referral criteria
Preparatory phase
• Steering committee  identiﬁed putative time-based criteria and needs-based criteria for an outpatient
 palliative-care referral on the basis of a systematic literature review and discussions
• Survey construction and testing
• Identiﬁcation and invitation of experts (total number of panellists included=60)
First Delphi round (Sept 28, 2015–0ct 26, 2015)
• Panellists rated their level of agreement on 20 time-based criteria and 36 needs-based criteria
• Panellists provided their demographic data
Second Delphi round (Dec 7, 2015–Jan 4, 2016)
• Panellists classiﬁed 20 time-based criteria and 39 needs-based criteria into the following categories:
 – Major criterion=meeting this criterion alone is appropriate for palliative-care referral
 – Minor criterion=this criterion could support referral in combination with other criteria
 – Inappropriate=this criterion should not be used to trigger palliative-care referral
• Panellists ranked the importance of each criterion
Third Delphi round (Jan 18, 2016–Feb 15, 2016)
• Panellists reassessed each of the two major time-based  criteria and 11 major needs-based criteria for inclusion
• Panellists rated the major criteria regarding their clarity, objectivity, amenability to be assessed, utility,
 and usefulness
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Findings
60 experts fulﬁ lled our eligibility criteria and agreed to be 
part of the panel. 59 (98%) responded in the ﬁ rst round, 
56 (93%) in the second, and 58 (97%) in the third. Most 
of the panellists were male (n=38 [63%]) and dually 
trained in palliative care and oncology (n=32 [54%]). They 
reported a median of 10 years’ experience (IQR 7·0–18·5) 
in palliative care and 12 years’ experience (8–20) in 
oncology practice (appendix).
In the ﬁ rst Delphi round, more than 70% of panellists 
marked 22 (61%) of 36 needs-based criteria and six (30%) 
of 20 time-based criteria as “appropriate” to trigger 
outpatient palliative-care referral (ﬁ gure 2, table 1). In the 
second Delphi round, panellists classiﬁ ed nine (23%) of 
the needs-based criteria and two (10%) of the time-based 
criteria as major, 23 (59%) of the needs-based criteria and 
13 (65%) of the time-based criteria as minor criteria, and 
seven (18%) of the need-based criteria and ﬁ ve (25%) of 
the time-based criteria as inappropriate (table 1).
In the third Delphi round, panellists were asked to 
provide their ﬁ nal decision about the appropriateness 
of each of the 11 major criteria identiﬁ ed during the 
second round as triggers for outpatient palliative-care 
referral. All 11 items achieved greater than 70% 
agreement as major criteria in both the second and 
third rounds (table 2). Responses to criteria remained 
stable between the second and third rounds, except for 
the criterion concerning spiritual or existential crisis, 
for which the level of agreement signiﬁ cantly increased 
(71% vs 91%; p=0·007).
The highest levels of agreement were for patient distress, 
including severe physical symptoms (100% agreement), 
severe emotional symptoms (97% agreement), request 
for hastened death (96% agreement), and spiritual or 
existential crisis (91% agreement; table 2). The two 
time-based criteria—within 3 months of diagnosis for 
patients with median survival of 1 year or less and 
progressive disease despite second-line systemic therapy—
both had 88% agreement (table 2).
On the numeric rating scale, the median scores for 
the major criteria were 9 (IQR 8–10) for “clearly stated”, 
8 for “objective in nature” (7–9), and 8 for “could be 
assessed accurately” (7–9). Panellists’ scores also 
suggested that the major criteria could be used for 
routine screening in oncology practice (median 8 
[IQR 7–9]), and were useful to facilitate outpatient 
palliative-care referral at their own institution (8 [7–9]) 
and in their own country (8 [7–9]).
Discussion
In this Delphi survey, international experts identiﬁ ed 
11 major criteria and 36 minor criteria to trigger palliative-
Figure 2: Most appropriate timing to refer a patient with advanced cancer to outpatient palliative care
We asked panellists to independently state the appropriateness of timing of referral with a ﬁ ve-point Likert scale (“much too early”, “too early”, “appropriate”, 
“too late”, or “much too late”) in the ﬁ rst Delphi round. A consensus was deﬁ ned as a minimum of 70% of experts rating timing as “appropriate”. ECOG=Eastern 
Cooperative Oncology Group.
Prognosis
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Cancer diagnosis
Within 1 month of diagnosis for patients with median survival ≤1 year
Within 3 month of diagnosis for patients with median survival ≤1 year
Within 6 month of diagnosis for patients with median survival ≤1 year
Within 1 month of diagnosis for patients with median survival >1–2 years
Within 3 month of diagnosis for patients with median survival >1–2 years
Within 6 month of diagnosis for patients with median survival >1–2 years
Within 12 months of diagnosis for patients with median survival >1–2 years
Treatment trajectory
Progressive disease despite ﬁrst-line systemic therapy
Progressive disease despite second-line systemic therapy
No further standard treatment options
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Round one (N=59)* Round two (N=56)* Category
Agreement, n (%) Appropriate as major 
criterion, n (%)
Appropriate but not as 
major criterion, n (%)
Importance† 
(range)
Needs-based criteria
Hypercalcaemia 35 (60%) 6 (11%) 40 (71%) 5 (4–6) Minor
Brain or leptomeningeal metastases 52 (90%) 41 (73%) 14 (25%) 8 (6–9) Major
Liver metastases 40 (69%) 12 (21%) 38 (68%) 6 (5–7) Minor
Bone metastases 36 (62%) 10 (18%) 42 (75%) 6 (5–7) Minor
Spinal cord compression or cauda equina 45 (78%) 41 (75%) 14 (25%) 8 (7–9) Major
Lymphangiectic carcinomatosis 49 (84%) 34 (61%) 21 (38%) 8 (6–9) Minor
Peritoneal carcinomatosis 50 (86%) 24 (44%) 29 (53%) 7 (5–8) Minor
Delirium 49 (84%) 44 (79%) 11 (20%) 8 (8–9) Major
Superior vena cava syndrome 42 (72%) 15 (27%) 37 (66%) 6 (5–8) Minor
Malignant eﬀ usions 43 (74%) 8 (14%) 44 (79%) 6 (5–7) Minor
Malignant ascites 44 (76%) 12 (21%) 39 (70%) 6 (5–7) Minor
Recent admission to intensive-care unit for cancer-
related complications or symptoms
45 (78%) 30 (55%) 24 (44%) 7 (6–9) Minor
Recent hospital admission for cancer-related 
complications or symptoms
43 (74%) 25 (46%) 28 (52%) 7 (6–8) Minor
Recent emergency-department attendance for cancer-
related complications or symptoms
39 (68%) 19 (34%) 35 (63%) 6 (5–8) Minor
Grade III or IV non-haematological toxicity 32 (56%) 5 (9%) 34 (63%) 5 (3–6) Minor
Mild physical symptoms (eg, pain, dyspnoea, or nausea 
scored 1–3 on a ten-point scale)
20 (35%) 1 (2%) 21 (38%) 3 (1–5) Exclude
Moderate physical symptoms (eg, pain, dyspnoea, or 
nausea scored 4–6 on a ten-point scale)
52 (90%) 18 (32%) 37 (66%) 6 (5–7) Minor
Severe physical symptoms (eg, pain, dyspnoea, or 
nausea scored 7–10 on a ten-point scale)
56 (97%) 55 (98%) 1 (2%) 9 (9–10) Major
Mild emotional symptoms (eg, depression or anxiety 
scored 1–3 on a ten-point scale)
23 (40%) 2 (4%) 24 (44%) 3 (2–6) Exclude
Moderate emotional symptoms (eg, depression or 
anxiety scored 4–6 on a ten-point scale)
51 (88%) 19 (35%) 36 (65%) 7 (5–8) Minor
Severe emotional symptoms (eg, depression or anxiety 
scored 7–10 on a ten-point scale)
57 (100%) 47 (84%) 9 (16%) 9 (8–10) Major
Pre-cachexia (<5% weight loss in past 3 months) 24 (42%) 3 (5%) 29 (52%) 4 (2–6) Exclude
Cachexia (>5% weight loss in past 3 months) 43 (75%) 22 (39%) 31 (55%) 7 (5–8) Minor
Severe hypoalbuminaemia (<25 g/L) 44 (76%) 14 (25%) 36 (64%) 6 (5–7) Minor
Financial distress 26 (45%) 3 (5%) 24 (43%) 4 (2–5) Exclude
Family discord 39 (67%) 9 (16%) 37 (66%) 5 (4–7) Minor
Inadequate social support 47 (81%) 25 (45%) 29 (52%) 7 (5–8) Minor
Caregiver distress 50 (86%) 29 (53%) 26 (47%) 7 (6–8) Minor
Health-care professional distress 38 (66%) 11 (20%) 32 (57%) 5 (4–7) Minor
Spiritual or existential crisis 50 (86%) 39 (71%) 15 (27%) 8 (7–9) Major
Request for hastened death 51 (88%) 49 (88%) 6 (11%) 9 (8–10) Major
History of drug or alcohol misuse 24 (41%) 1 (2%) 29 (52%) 4 (3–6) Exclude
Need to start strong opioids 38 (66%) 7 (13%) 36 (64%) 6 (3–7) Minor
Phase I therapy involvement 31 (54%) 11 (20%) 22 (39%) 5 (2–6) Exclude
Patient request 52 (90%) 48 (86%) 8 (14%) 9 (8–10) Major
Assistance with decision making or care planning 55 (95%) 49 (88%) 7 (13%) 9 (8–10) Major
Unrealistic hope or denial N/A 13 (23%) 41 (73%) 6 (5–8) Minor
Participation in phase 2 or 3 clinical trials N/A 5 (9%) 18 (33%) 3 (1–5) Exclude
Patient expected to have aggressive disease course at 
the time of diagnosis (eg, survival <6 months)
N/A 35 (63%) 20 (36%) 7 (5–9) Minor
(Table 1 continues on next page)
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care referral. The presence of any major criterion alone 
could be suﬃ  cient to trigger an outpatient palliative-care 
referral. With further validation, these criteria could be 
useful as triggers to initiate referral of patients with 
cancer to a specialist outpatient palliative-care clinic.
Outpatient palliative-care clinics are becoming 
increasingly common in cancer centres, and are 
imperative to facilitate timely referrals.8,17 Although 
several researchers have proposed referral criteria for 
inpatient palliative care,18 consensus on outpatient 
referral criteria has been limited.16 We were surprised 
by the large number of criteria that reached consensus 
in this study, despite the diverse professional and 
cultural backgrounds of the 60 panellists. This ﬁ nding 
suggests that some universal patient phenotypes could 
be appropriate for outpatient palliative care, irrespective 
of health-care system or boundaries. The high response 
rate in all three rounds was reassuring, and implies 
that the issue is topical and of high relevance to clinical 
practice.
Four of the major needs-based criteria were related to 
severe distress, which makes sense—palliative care was 
developed as a discipline to help to alleviate suﬀ ering, 
and specialists have acquired substantial expertise in 
symptom management.19,20 Several studies1–4 have shown 
that outpatient palliative-care referral is associated with 
improvement in symptom control and quality of life. In 
view of the increasing emphasis on primary palliative 
care delivered by oncologists, our panellists suggested 
that patients with any severe symptom should be 
referred, although having one moderate symptom alone 
might not be adequate for referral. Although 
Round one (N=59)* Round two (N=56)* Category
Agreement, n (%) Appropriate as major 
criterion, n (%)
Appropriate but not as 
major criterion, n (%)
Importance† 
(range)
(Continued from previous page)
Time-based criteria
Physician-estimated life expectancy >24 months 14 (25%) 0 (0%) 28 (50%) 3 (1–5) Exclude
Physician-estimated life expectancy 12–24 months 38 (66%) 6 (11%) 43 (77%) 5 (3–7) Minor
Physician-estimated life expectancy 6–12 months 50 (86%) 35 (63%) 18 (32%) 8 (6–9) Minor
Physician-estimated life expectancy 3–6 months 29 (51%) 36 (64%) 18 (32%) 9 (7–10) Minor
Physician-estimated life expectancy 1–3 months 12 (21%) 27 (48%) 12 (21%) 8 (5–10) Minor
Physician estimated life expectancy <1 month 2 (3%) 17 (30%) 9 (16%) 8 (3–10) Exclude
Within 1 month of diagnosis of advanced or incurable 
cancer with median survival of 1 year or less
50 (86%) 36 (65%) 17 (31%) 8 (7–9) Minor
Within 3 months of diagnosis of advanced or incurable 
cancer with median survival of 1 year or less
45 (78%) 40 (71%) 14 (25%) 8 (7–9) Major
Within 6 months of diagnosis of advanced or incurable 
cancer with median survival of 1 year or less
24 (41%) 18 (32%) 22 (39%) 6 (5–8) Minor
Within 1 month of diagnosis of advanced or incurable 
cancer with median survival of 1–2 years
38 (67%) 8 (14%) 36 (64%) 5 (4–7) Minor
Within 3 months of diagnosis of advanced or incurable 
cancer with median survival of 1–2 years
39 (67%) 11 (20%) 38 (68%) 6 (4–7) Minor
Within 6 months of diagnosis of advanced or incurable 
cancer with median survival of 1–2 years
36 (62%) 18 (32%) 33 (59%) 5 (4–8) Minor
Within 12 months of diagnosis of advanced or incurable 
cancer for patients with median survival of 1–2 years
23 (40%) 7 (13%) 31 (56%) 5 (4–7) Exclude
Diagnosis of advanced cancer with progressive disease 
despite ﬁ rst-line systemic therapy (incurable)
50 (88%) 35 (63%) 19 (34%) 8 (6–9) Minor
Diagnosis of advanced cancer with progressive disease 
despite second-line systemic therapy (incurable)
43 (75%) 39 (70%) 15 (27%) 8 (7–9) Major
Diagnosis of advanced cancer with no further standard 
palliative cancer treatment options (incurable)
34 (59%) 32 (57%) 17 (30%) 8 (6–9) Minor
ECOG performance status 0–1 39 (68%) 6 (11%) 29 (52%) 5 (2–6) Exclude
ECOG performance status 2 51 (89%) 18 (32%) 33 (59%) 6 (5–8) Minor
ECOG performance status 3 23 (40%) 25 (45%) 20 (36%) 7 (5–9) Minor
ECOG performance status 4 10 (17%) 19 (34%) 8 (14%) 8 (3–9) Exclude
During the second round, the panellists were asked to classify each criterion as a major criterion or a minor criterion, or to exclude it. A criterion was classiﬁ ed as minor if it did 
not reach consensus as a major criterion, but had 70% or greater of the respondents agreeing in the ﬁ rst round. N/A=not applicable. ECOG=Eastern Cooperative Oncology 
Group. *Because not all respondents answered all questions, in some instances the denominator used to calculate the percentages was diﬀ erent. †Panellists scored 
importance on a numeric scale ranging from 0 (“not at all”) to 10 (“very much”). 
Table 1: Putative criteria for outpatient palliative care referral in ﬁ rst two Delphi rounds
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physician-hastened death is a highly controversial 
topic,21 palliative care was generally agreed to have an 
important role in exploration of these requests and 
discussion of alternative options to address suﬀ ering.
A major needs-based criterion was related to assistance 
with decision making or care planning, or both, which 
are key palliative-care domains.22,23 Timely introduction of 
palliative care can facilitate end-of-life discussions, 
enhance understanding of an illness, increase prognostic 
awareness, and improve end-of-life care outcomes.5,24–26 
Because every patient with advanced disease could 
potentially beneﬁ t from assistance with decision making 
or care planning, this criterion is less speciﬁ c than the 
symptom distress criteria. Further research is needed to 
determine the proportion of patients and oncologists 
who perceive that they need extra assistance related to 
palliative care and the speciﬁ c decisions associated 
with this request, the optimal timing, and the 
patient-related and oncologist-related factors associated 
with a greater likelihood of requesting such services.
Three other major needs-based criteria involved 
patients with neurological complications of cancer—
namely, brain metastases, spinal cord compression, and 
delirium. These major sentinel events mark the 
beginning of progressive functional decline and are often 
associated with pronounced psychological concerns and 
caregiver distress.27,28 Furthermore, patients with these 
neurological complications often have shorter survival 
than those without neurological complications. Because 
of the anticipated care needs, these patients are highly 
suitable for outpatient palliative-care referral if they have 
not been referred already on the basis of other criteria.
The ideal time for patients to be referred to outpatient 
palliative care has been debated. Our panellists identiﬁ ed 
two major time-based criteria—within 3 months of 
advanced cancer diagnosis for patients with life 
expectancy of 1 year or less, and progressive disease 
despite two lines of palliative systemic (disease-modifying) 
therapy—as the most appropriate timing criteria for 
outpatient palliative-care referral. Both of these criteria 
involve patients with limited prognosis, which might 
represent the so-called Goldilocks zone. On the one 
hand, referrals that are too late might deprive patients of 
the full beneﬁ ts associated with longitudinal palliative 
care, such as timely symptom management to minimise 
crises and end-of-life discussions to attenuate the 
aggressiveness of end-of-life care. On the other hand, 
referrals that are too early might result in patients being 
seen by palliative-care specialists when they have few 
concerns and thus might not derive as much beneﬁ t. 
Furthermore, a large volume of early consultations could 
potentially overwhelm the limited infrastructure of 
palliative-care programmes. Neither performance status 
nor prognosis were included as major criteria, perhaps 
because of the variability in their determination.29,30
The panellists also identiﬁ ed 36 minor criteria, which 
might be used to support referral in aggregate, but might 
not individually be adequate to trigger a referral in the 
absence of other factors. One question is whether a 
referral score should be created, with diﬀ erent weights 
assigned for each criterion on the basis of its relative 
importance (eg, 2 points for a major criterion, 1 point for 
a minor criterion). The advantage of a score is that such a 
system would allow prioritisation and customisation of 
the referral process within each institution (eg, higher 
threshold for resource-limited settings), and ultimately 
standardisation of the referral process. However, referral 
scores might be cumbersome to apply,31 and further 
research is needed to derive and validate them.
Our list of consensus criteria represents a key step 
towards standardisation of the referral process, which is 
presently haphazard. Importantly, these criteria should 
serve as guiding principles, and should augment rather 
than replace clinical judgment. An oncologist might 
decide to refer a patient to palliative care at any time, 
even if this patient does not meet any of the criteria. 
Future research should assess the proportion of patients 
who meet each of these criteria in the oncology setting, 
the feasibility of applying these criteria in clinical 
practice, and the barriers to implementation as 
perceived by patients, families, and oncologists in 
diﬀ erent settings. Furthermore, these criteria will need 
to be customised for each institution on the basis of 
resource availability and local health-care culture. More 
studies are also needed to examine the validity of these 
criteria to determine whether application improves 
Category Second-round 
agreement, 
n (%)
Third-round 
agreement, 
n (%)
p*
Needs-based criteria
Severe physical symptoms (eg, pain, dyspnoea 
or nausea scored 7–10 on a ten-point scale)
Distress 55 (98%) 58 (100%) >0·99
Severe emotional symptoms (eg, depression or 
anxiety scored 7–10 on a ten-point scale)
Distress 47 (84%) 56 (97%) 0·07
Request for hastened death Distress 49 (88%) 55 (96%) 0·13
Spiritual or existential crisis Distress 39 (71%) 53 (91%) 0·007
Assistance with decision making or care 
planning
Other 49 (88%) 55 (95%) 0·45
Patient request Other 48 (86%) 55 (95%) 0·34
Delirium Neurological 44 (79%) 51 (88%) 0·42
Brain or leptomeningeal metastases Neurological 41 (73%) 43 (74%) >0·99
Spinal cord compression or cauda equina Neurological 41 (75%) 42 (72%) 0·85
Time-based criteria
Within 3 months of diagnosis of advanced or 
incurable cancer for patients with median 
survival of 1 year or less
Disease 
trajectory
40 (71%) 51 (88%) 0·05
Diagnosis of advanced cancer with progressive 
disease despite second-line systemic therapy 
(incurable)
Disease 
trajectory
39 (70%) 51 (88%) 0·06
N=56 in the second round; N=58 in the third round. Because not all respondents answered all questions, in some 
instances the denominator used to calculate the percentages was diﬀ erent. *The McNemar test was used to examine 
the concordance in response between the second and third rounds. 
Table 2: Major criteria for outpatient palliative care referral in third Delphi round
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patient outcomes and is cost-eﬀ ective.5 Previous studies 
have consistently shown that oncologists’ attitudes 
towards palliative care vary widely, which can act as a 
barrier to referral.32,33 Whether standardised referral 
criteria can help to reduce this variability would be 
useful to establish.
Our study has several limitations. First, the Delphi 
survey was based on the input of highly selected experts 
by design, which could incur bias. For example, dually 
trained palliative oncologists comprised more than half 
the panel, and might have a higher or lower threshold for 
referral than the typical oncologist. Importantly, we 
speciﬁ cally invited individuals who were active clinically, 
had outpatient palliative-care clinics in their institution, 
and had relevant expertise to address the research 
question because of their academic or administrative 
experience. Thus, these experts have a good understanding 
not only of the topic, but also of the realities of clinical 
practice, such as the level of primary palliative care 
delivered by oncologists locally and how specialty 
palliative care can complement their practice. Before the 
proposed referral criteria can be adopted in routine 
practice, however, further studies are needed to examine 
them from the perspectives of key stakeholders, including 
general oncologists, palliative-care specialists, patients 
and their families. Second, most experts are from high-
income nations because palliative care and outpatient 
clinics are more established. Third, we asked experts to 
focus on developing an ideal set of criteria at secondary or 
tertiary care hospitals with an interdisciplinary 
palliative-care team in place, assuming that service 
delivery is not an issue. Given that resources are often 
limited in reality, these criteria would need to be further 
customised before application at the institution level. 
Finally, we focused on specialty palliative-care referral 
only; the amount of primary palliative care that oncologists 
should be delivering is beyond the scope of this study, and 
is being actively investigated by other groups.34
Our international panel reached consensus on 11 major 
and 36 minor criteria for outpatient palliative-care 
referral for patients with advanced cancer being treated 
at secondary or tertiary care hospitals. These criteria 
should be further tailored to each institution, and could 
help streamline and standardise clinical practice, 
research, and resources related to palliative-care access 
for patients with cancer.
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